Case with triple-negative breast cancer shows overexpression of both cFOS and TGF-β1 in node-positive tissue

Personalized Medicine
Vesna IvanovićBogomir Dimitrijević

Abstract

We present herein a case report style article on a rare advanced triple-negative breast cancer (TNBC) patient with 6-month disease-free interval, and 10-month overall survival. Our results demonstrate that the poor clinical outcome of this patient was associated with pronounced, more than fivefold higher, overexpression of both cFOS and TGF-β1 proteins in its metastatic nodal tissue extracts, when compared with the values of the two non-TNBC controls (with 'zero' disease-free interval and overall survival). This original observation suggests, for the first time, that both the cFOS and TGF-β1 may be considered as a pair of biomarkers for an early assessment of poor prognosis for TNBC patients. The possible clinical implication of this observation is discussed.

References

Apr 1, 1990·Molecular and Cellular Biology·S J KimA B Roberts
Nov 6, 2003·Cancer·James S MichaelsonBarbara Smith
Oct 4, 2005·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Karin Milde-Langosch
Mar 2, 2010·Journal of the National Cancer Institute·M de BoerV C G Tjan-Heijnen
Jul 20, 2012·International Journal of Biological Sciences·Erin C ConnollyRosemary J Akhurst
Oct 4, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G von Minckwitz, M Martin
Feb 9, 2013·The Journal of Clinical Investigation·Neil E BholaCarlos L Arteaga
Mar 12, 2013·Cancer Letters·Chevaun D MorrisonWilliam P Schiemann
Nov 19, 2013·Biomolecules & Therapeutics·Yhun Yhong SheenJeong-Seok Nam
Jun 5, 2015·British Journal of Pharmacology·Vinayak S JamdadeNeeraj Sinha
Jul 22, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Catherine Van PoznakLyndsay N Harris
Aug 2, 2015·Experimental and Molecular Pathology·Abeer BahnassyAbdel-Rahman N Zekri

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Methods Mentioned

BETA
ELISA
Assay

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.